Our approach of characterizing the proteomic profile of histopathology-targeted areas was successful in depicting temporo-spatial heterogeneity in diffuse astrocytomas and identified HMGB2 as a valuable, yet poorly explored, putative enabler of glioma progression. Here, HMGB2 is linked to diffuse astrocytoma.